Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flow from operating activities:
Net loss	$ (44,599)	$ (205,842)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,046	7,028
Non cash lease expense	125	(62)
Provision for credit losses	222	456
Provision for inventory obsolescence	(50)
Change in fair value of warrant liabilities	1,156	(6,788)
Goodwill impairment	0	112,347
IPR&D impairment		107,800
Stock-based compensation expense	8,628	11,442
Change in fair value of contingent consideration		(104,339)
Acquired in-process research and development		3,000
Issuance of common stock for stem-cells to be used in research and development		1,000
Issuance of common stock to Palantir as consideration for settlement agreement	175
Issuance of common stock to Yorkville for debt extension and SEPA commitment fee	317	712
Discounts arising from RWI loan arrangement - related party		2,151
Fair value of warrant modification for professional services		403
Change in fair value of contingent stock consideration		(159)
Loss on extinguishment of debt	3,908	0
Change in fair value of debt	694	354
Non cash interest expense	3,217
Other, net	(285)	2,012
Changes in assets and liabilities:
Accounts receivable	1,054	(118)
Inventory	5,653	(1,605)
Prepaid expenses and other assets	109	2,179
Accounts payable	1,312	6,754
Accrued expenses and other liabilities	7,237	1,533
Accrued R&D software	(3,500)	24,161
Lease liabilities - operating	274	172
Deferred revenue	312	1,065
Net cash used in operating activities	(7,995)	(34,344)
Cash flow from investing activities:
Capital expenditures	(105)	(468)
Proceeds from Sanuwave convertible note receivable	2,175
Purchase of acquired in-process research and development		(3,000)
Net cash provided by (used in) investing activities	2,070	(3,468)
Cash flow from financing activities:
Proceeds from warrants and short-term debt - related parties	15,000	18,369
Proceeds from registered direct offering		9,000
Proceeds from the exercise of stock options		304
Repayments of short-term debt - unaffiliated	(17,374)	(16,811)
Proceeds from issuance of short-term debt - unaffiliated	2,993	2,000
Payment of SEPA commitment fee	(25)
Repayments of short-term debt - related parties	(106)
Proceeds from PIPE financing	6,000	12,750
Proceeds from the sale of common stock in ATM offering		136
Payments of PIPE and other issuance costs		(1,553)
Tax withholding on vesting of restricted stock units	(430)	(87)
Net cash provided by financing activities	6,058	24,108
Net increase (decrease) in cash, cash equivalents and restricted cash	133	(13,704)
Cash, cash equivalents and restricted cash at beginning of period	10,163	28,802
Cash, cash equivalents and restricted cash at end of period	10,296	15,098
Supplemental disclosure of cash flow information:
Cash paid for interest	144	1,073
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(56)	(752)
Modification of C.V. Starr warrants in connection with forbearance	51
Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification		(2,083)
Issuance of RWI warrants in connection with forbearance	1,162
Issuance of warrants on senior secured bridge loan		2,002
Reclassification of warrants from liability classified to equity classified	$ 2,970
PIPE related costs included in accrued expenses		(69)
Common stock issued for short-term debt conversion		4,599
Interest accrued on senior secured loans within long-term debt - related parties		$ (1,229)